$CORT
Corcept Therapeutics Inc

2022 Q3 Form 10-Q Financial Statement

#000162828022020731 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $101.7M $103.4M $93.69M
YoY Change 5.82% 12.88% 17.94%
Cost Of Revenue $1.339M $1.316M $1.250M
YoY Change 5.02% -4.91% -1.42%
Gross Profit $100.4M $102.1M $92.44M
YoY Change 5.83% 13.15% 18.25%
Gross Profit Margin 98.68% 98.73% 98.67%
Selling, General & Admin $35.16M $37.81M $37.55M
YoY Change 15.16% 25.92% 27.25%
% of Gross Profit 35.03% 37.05% 40.62%
Research & Development $33.29M $32.83M $28.12M
YoY Change 18.51% 16.27% -3.11%
% of Gross Profit 33.16% 32.16% 30.42%
Depreciation & Amortization $195.0K $116.0K $288.0K
YoY Change -27.51% -45.79% 13.39%
% of Gross Profit 0.19% 0.11% 0.31%
Operating Expenses $68.46M $70.64M $65.67M
YoY Change 16.77% 21.24% 12.2%
Operating Profit $31.93M $31.43M $26.77M
YoY Change -11.86% -1.6% 36.31%
Interest Expense $1.070M $630.0K $80.00K
YoY Change 1386.11% 472.73% -71.43%
% of Operating Profit 3.35% 2.0% 0.3%
Other Income/Expense, Net $1.070M $630.0K $80.00K
YoY Change 1386.11% 472.73% -70.91%
Pretax Income $33.00M $32.06M $26.85M
YoY Change -9.09% 0.03% 34.83%
Income Tax -$1.600M $4.700M $4.100M
% Of Pretax Income -4.85% 14.66% 15.27%
Net Earnings $34.61M $27.41M $22.80M
YoY Change 13.58% 3.35% -2.85%
Net Earnings / Revenue 34.02% 26.51% 24.33%
Basic Earnings Per Share $0.32 $0.26 $0.22
Diluted Earnings Per Share $0.30 $0.24 $0.20
COMMON SHARES
Basic Shares Outstanding 107.1M shares 106.3M shares 106.0M shares
Diluted Shares Outstanding 116.6M shares 115.4M shares 115.0M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $396.3M $370.1M $345.5M
YoY Change 9.67% 0.03% -7.37%
Cash & Equivalents $50.24M $35.35M $61.86M
Short-Term Investments $346.0M $334.7M $283.7M
Other Short-Term Assets $20.68M $15.36M $10.44M
YoY Change 128.08% 70.66% 9.85%
Inventory $6.046M $5.437M $5.079M
Prepaid Expenses
Receivables $29.41M $28.16M $27.18M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $452.4M $419.0M $388.2M
YoY Change 12.57% 1.89% -5.23%
LONG-TERM ASSETS
Property, Plant & Equipment $801.0K $862.0K $726.0K
YoY Change -34.67% -39.04% -50.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.895M $11.89M $22.57M
YoY Change -96.34% -88.3% -72.41%
Other Assets $5.081M $1.834M $2.984M
YoY Change 23.75% -55.7% -40.68%
Total Long-Term Assets $80.85M $77.32M $79.90M
YoY Change -55.94% -50.82% -44.04%
TOTAL ASSETS
Total Short-Term Assets $452.4M $419.0M $388.2M
Total Long-Term Assets $80.85M $77.32M $79.90M
Total Assets $533.3M $496.4M $468.1M
YoY Change -8.91% -12.69% -15.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.178M $8.246M $9.269M
YoY Change 24.7% -10.53% 33.0%
Accrued Expenses $29.41M $24.74M $32.66M
YoY Change 20.99% 15.01% 81.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.07M $49.06M $57.24M
YoY Change 18.57% 8.05% 40.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.823M $4.981M $3.068M
YoY Change 1552.06% 1135.98% 206.8%
Total Long-Term Liabilities $6.823M $4.981M $3.068M
YoY Change 1552.06% 1135.98% 206.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.07M $49.06M $57.24M
Total Long-Term Liabilities $6.823M $4.981M $3.068M
Total Liabilities $59.89M $54.04M $60.31M
YoY Change 32.59% 17.97% 44.99%
SHAREHOLDERS EQUITY
Retained Earnings $279.8M $245.2M $217.8M
YoY Change 71.74% 85.12% 105.59%
Common Stock $649.0M $626.1M $608.8M
YoY Change 13.55% 12.96% 13.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $473.4M $442.3M $407.8M
YoY Change
Total Liabilities & Shareholders Equity $533.3M $496.4M $468.1M
YoY Change -8.91% -12.69% -15.26%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $34.61M $27.41M $22.80M
YoY Change 13.58% 3.35% -2.85%
Depreciation, Depletion And Amortization $195.0K $116.0K $288.0K
YoY Change -27.51% -45.79% 13.39%
Cash From Operating Activities $33.65M $18.04M $35.25M
YoY Change -30.91% -59.33% 38.65%
INVESTING ACTIVITIES
Capital Expenditures -$351.0K -$19.00K $12.00K
YoY Change 120.75% -86.9% -90.48%
Acquisitions
YoY Change
Other Investing Activities -$4.439M -$41.78M -$50.48M
YoY Change -82.69% -267.77% 1477.63%
Cash From Investing Activities -$4.790M -$41.80M -$50.50M
YoY Change -81.44% -268.83% 1437.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.96M -2.756M -$506.0K
YoY Change -40.95% -89.43% -98.9%
NET CHANGE
Cash From Operating Activities 33.65M 18.04M $35.25M
Cash From Investing Activities -4.790M -41.80M -$50.50M
Cash From Financing Activities -13.96M -2.756M -$506.0K
Net Change In Cash 14.90M -26.52M -$15.76M
YoY Change -2107.68% -161.61% -33.83%
FREE CASH FLOW
Cash From Operating Activities $33.65M $18.04M $35.25M
Capital Expenditures -$351.0K -$19.00K $12.00K
Free Cash Flow $34.00M $18.06M $35.24M
YoY Change -30.42% -59.42% 39.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Local Phone Number
LocalPhoneNumber
327-3270
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001088856
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50679
dei Entity Registrant Name
EntityRegistrantName
CORCEPT THERAPEUTICS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0487658
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Commonwealth Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
650
dei Trading Symbol
TradingSymbol
CORT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
107105078 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35346000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77617000 usd
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
334740000 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
145918000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28164000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27625000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
5437000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
4988000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15358000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10315000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
419045000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
266463000 usd
CY2022Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
11978000 usd
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12962000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2264000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
514000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
862000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1002000 usd
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
11890000 usd
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
112277000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1834000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3083000 usd
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
48491000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
27455000 usd
CY2022Q2 us-gaap Assets
Assets
496364000 usd
CY2021Q4 us-gaap Assets
Assets
423756000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8246000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6908000 usd
CY2022Q2 cort Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
13803000 usd
CY2021Q4 cort Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
12442000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24744000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27665000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2264000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
526000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
49057000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
47541000 usd
CY2022Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
4981000 usd
CY2021Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
409000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
54038000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
47950000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
128000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
127000 usd
CY2022Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
426814000 usd
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
410411000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
625976000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
591349000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2141000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-227000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
245177000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
194968000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
442326000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
375806000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
496364000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
423756000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103386000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
91588000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
197074000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
171025000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1316000 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1384000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2566000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2652000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32825000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28232000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60945000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57254000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37813000 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30029000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
75362000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59538000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
71954000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
59645000 usd
us-gaap Costs And Expenses
CostsAndExpenses
138873000 usd
us-gaap Costs And Expenses
CostsAndExpenses
119444000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
31432000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
31943000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
58201000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
51581000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
630000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
110000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
710000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
385000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32062000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32053000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
58911000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
51966000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4650000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5530000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8702000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1978000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27412000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
26523000 usd
us-gaap Net Income Loss
NetIncomeLoss
50209000 usd
us-gaap Net Income Loss
NetIncomeLoss
49988000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
27398000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
27398000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
26523000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
26523000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
50196000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
50196000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
49988000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
49988000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106289000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116294000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106151000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116555000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115399000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126680000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115222000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128204000 shares
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27412000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
26523000 usd
us-gaap Net Income Loss
NetIncomeLoss
50209000 usd
us-gaap Net Income Loss
NetIncomeLoss
49988000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
149000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
16000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
472000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
77000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-470000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-50000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1489000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-242000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-320000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
16000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-425000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
42000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
26622000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
26489000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
48295000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
49788000 usd
us-gaap Profit Loss
ProfitLoss
50209000 usd
us-gaap Profit Loss
ProfitLoss
49988000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
21367000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
21169000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1870000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2471000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
404000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
514000 usd
cort Accretion Expense Income
AccretionExpenseIncome
-20565000 usd
cort Accretion Expense Income
AccretionExpenseIncome
-2061000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1066000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
985000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
539000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1422000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-655000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1858000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5043000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2047000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1249000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-860000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
680000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1304000 usd
cort Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1361000 usd
cort Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-591000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2921000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
328000 usd
CY2022Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
1700000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
4572000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
5000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1078000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-992000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
53287000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
69761000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
245000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
87306000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
244971000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
179571000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
223268000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92296000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21458000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1932000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8786000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
62711000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5194000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
18054000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3262000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-71979000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42271000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19240000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77617000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76190000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35346000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95430000 usd
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
11209000 usd
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
7704000 usd
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
2816000 usd
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
0 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
523338000 usd
cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P2Y
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10083000 usd
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
33540000 usd
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
22520000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10142000 usd
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-166000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
23465000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
510802000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6661000 usd
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
29170000 usd
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3238000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11131000 usd
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-34000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
26523000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
522675000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
375806000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6544000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
7037000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10825000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1124000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
22797000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
407811000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6597000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
9366000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10662000 usd
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-790000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27412000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
442326000 usd
cort Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
4 series
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1400000 usd
CY2022Q2 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
11374000 usd
CY2021Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
11450000 usd
CY2022Q2 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6041000 usd
CY2021Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6500000 usd
CY2022Q2 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
17415000 usd
CY2021Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
17950000 usd
CY2022Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
11978000 usd
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12962000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
5437000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
4988000 usd
CY2022Q2 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
1351000 usd
CY2021Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
842000 usd
CY2022Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1138000 usd
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1351000 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4191000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3927000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3329000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2925000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
862000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1002000 usd
CY2022Q2 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
12015000 usd
CY2021Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
11174000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8873000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13339000 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
744000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
150000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
623000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
809000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24744000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27665000 usd
CY2022Q2 cort Deposits For Clinical Trials
DepositsForClinicalTrials
1700000 usd
CY2021Q4 cort Deposits For Clinical Trials
DepositsForClinicalTrials
2900000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
361869000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
303283000 usd
cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P6M
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
530000 usd
CY2022Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 usd
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000 usd
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
578000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1108000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1044000 usd
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2021Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2816000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12M
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.048
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1157000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1157000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2314000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
50000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2264000 usd
cort Number Of Stock Option Plans
NumberOfStockOptionPlans
1 stockoptionplan
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0 shares
CY2022Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
56000 usd
CY2021Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
63000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
120000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
104000 usd
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10662000 usd
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
11131000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
21487000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
21273000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
27398000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
27398000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
26523000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
26523000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
50196000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
50196000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
49988000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
49988000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106289000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116294000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106151000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116555000 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9110000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10386000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9071000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
11649000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115399000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126680000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115222000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128204000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26000000 shares
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8700000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5500000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000000 usd
CY2022Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
600000 usd
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1000000 usd
CY2022Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
8100000 usd
CY2022Q2 cort Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance
UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance
2100000 usd

Files In Submission

Name View Source Status
0001628280-22-020731-index-headers.html Edgar Link pending
0001628280-22-020731-index.html Edgar Link pending
0001628280-22-020731.txt Edgar Link pending
0001628280-22-020731-xbrl.zip Edgar Link pending
cort-20220630.htm Edgar Link pending
cort-20220630.xsd Edgar Link pending
cort-20220630_cal.xml Edgar Link unprocessable
cort-20220630_def.xml Edgar Link unprocessable
cort-20220630_htm.xml Edgar Link completed
cort-20220630_lab.xml Edgar Link unprocessable
cort-20220630_pre.xml Edgar Link unprocessable
cort63022ex101.htm Edgar Link pending
cort63022ex102.htm Edgar Link pending
cort63022ex311.htm Edgar Link pending
cort63022ex312.htm Edgar Link pending
cort63022ex321.htm Edgar Link pending
cort63022ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending